What did they decide about providing fair biological access to human ES cell therapy?
These conclusions are reported in the November/December issue of The Hastings Center Report. Even though clinical trials with human ES cells, or more specialized cells obtained from them, are still many years away, the panel tried to determine the fairest, or most just, way to conduct clinical trials and therapies after the trials conclude. The panel members all agreed that clinical trials, the first attempts to see if human ES cells are safe and effective, should happen as fast as possible once they are ready to begin. Speed is obtained, in part, by being able to rapidly enroll participants into the clinical trial. If “matching” human ES cells and the recipient is important for these clinical trials, as currently expected, then the available ES cell lines should match as many people as possible. The panel recommends creating an ES stem cell “bank” that would match the most Americans with the fewest number of cell lines. Because the biology of “matching” depends largely on ancestry, th
Related Questions
- Is it fair to say that, as a human, you enjoy the chaos and beauty of wilderness and nature, but not enough to prefer it over right angles, sterilized order, pathological security and rigorous predictability?
- How do we deal with the ethical and safety issues around human stem cell research and therapy?
- What did they decide about providing fair biological access to human ES cell therapy?
